About Pathway Therapeutics

Pathway Therapeutics Ltd (Pathway) is an New Zealand based drug development
company established to discover and develop the next generation of novel,
differentiated, selective inhibitors of PI3-kinase (PI3K) for the treatment
of cancers and inflammatory diseases.

Company History

• $10 million Series A financing in June 2008
• Based in New Zealand with offices in San Francisco, CA

Management

• Julie Cherrington, Ph.D. – CEO
  (previously with Phenomix, Gilead, Sugen)

Platform

• Selective PI3K discovery and development program
• Technology from The University of Auckland
  • Drug discovery groups led by Professors William (Bill) Denny and Peter Shepherd

Therapeutic Focus

• Oncology opportunity: Selective inhibitors of PI3K kinase; alpha (α); delta (δ);
  and irreversible inhibitors of alpha (α)
• Non-Oncology opportunity: Selective inhibitors of delta (δ)

Milestones

• Lead selection in PI3 kinase inhibitor program in 2010
• Second generation programs focused on:
  • alpha or delta selective inhibitors
  • irreversible alpha selective inhibitors (sustained shutdown may improve efficacy)
• Seeking discovery and development collaborations to advance pipeline